Abiomed Inc (ABMD.OQ)
305.92USD
20 Apr 2018
$-0.53 (-0.17%)
$306.45
$306.01
$307.10
$303.02
109,130
148,079
$308.82
$122.84
About
Overall
| Beta: | 0.21 |
| Market Cap(Mil.): | $7,712.59 |
| Shares Outstanding(Mil.): | 44.10 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
BRIEF-Abiomed Announces European Approval For Impella 5.5(Tm)
* ABIOMED ANNOUNCES EUROPEAN APPROVAL (CE MARKING) FOR IMPELLA 5.5(TM) AND FIRST PATIENT TREATED AT UNIVERSITY HEART CENTER HAMBURG Source text for Eikon: Further company coverage:
BRIEF-Abiomed Announces European Approval (CE Marking) For Impella 5.5™
* ABIOMED ANNOUNCES EUROPEAN APPROVAL (CE MARKING) FOR IMPELLA 5.5™ AND FIRST PATIENT TREATED AT UNIVERSITY HEART CENTER HAMBURG Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
BRIEF-Abiomed Receives FDA Approval For Impella Cp® With Smartassist™ And Optical Sensor
* ABIOMED RECEIVES FDA APPROVAL FOR IMPELLA CP® WITH SMARTASSIST™ AND OPTICAL SENSOR
BRIEF-Abiomed To Appoint Todd Trapp Chief Financial Officer
* ABIOMED TO APPOINT NEW CHIEF FINANCIAL OFFICER TODD A. TRAPP
Abiomed to pay $3.1 million to settle case over lavish doctor meals
BOSTON Abiomed Inc has agreed to pay $3.1 million to resolve a U.S. probe into allegations that it sought to get doctors to use a line of heart pumps it produced by buying them lavish meals at some of the most expensive restaurants in the United States.
UPDATE 2-Abiomed to pay $3.1 mln to settle case over lavish doctor meals
BOSTON, March 8 Abiomed Inc has agreed to pay $3.1 million to resolve a U.S. probe into allegations that it sought to get doctors to use a line of heart pumps it produced by buying them lavish meals at some of the most expensive restaurants in the United States.
BRIEF-Abiomed Says Entered Settlement With U.S. DoJ Resolving Claims Related To Employee Meals
* ABIOMED - ON MARCH 6, ENTERED SETTLEMENT WITH U.S. DOJ RESOLVING CLAIMS ON CO'S REIMBURSEMENT OF EMPLOYEE EXPENSES FOR MEALS WITH HEALTHCARE PROVIDERS Source text: (http://bit.ly/2G9t6b6) Further company coverage:
Heart pump maker Abiomed settles U.S. kickback probe for $3.1 mln
BOSTON, March 8 Abiomed Inc has agreed to pay $3.1 million to resolve a U.S. investigation into allegations that it sought to induce doctors into using a line of heart pumps it produced by buying them lavish meals.
BRIEF-Abiomed Receives Approval For Expanded FDA Indication For High Risk PCI Procedures
* ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR HIGH RISK PERCUTANEOUS CORONARY INTERVENTION (PCI) PROCEDURES Source text for Eikon: Further company coverage:
BRIEF-Abiomed Receives Approval For Expanded FDA Indication For Cardiomyopathy With Cardiogenic Shock
* ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR CARDIOMYOPATHY WITH CARDIOGENIC SHOCK
Competitors
| Price | Chg | |
|---|---|---|
| Terumo Corp (4543.T) | ¥6,190 | +100.00 |
| Getinge AB (GETIb.ST) | 95.58kr | +0.46 |
| Teleflex Incorporated (TFX.N) | $271.03 | +1.39 |
| HeartWare International Inc (HTWR.OQ) | -- | -- |
| Abbott Laboratories (ABT.N) | $59.19 | -0.69 |
| St Jude Medical Inc (STJ.N) | -- | -- |
Estimates